Australian public assessment for blinatumomab (rch)

Patients with ALL are immunocompromised and consequently at increased risk for serious infections. In patients receiving Blincyto, serious infections, including sepsis, pneumonia, bacteraemia, opportunistic infections, and catheter site infections have been observed, some of … ................
................